









市场行情
/
股票
/
nasdaq-qgen
/

Qiagen NV

QGEN

48.290USD

-0.160-0.33%

收盘 01/09, 16:00（美东）报价延迟15分钟

10.45B总市值

25.83市盈率 TTM



Qiagen NV

48.290

-0.160-0.33%

概览公司财务分析

概览

公司

财务

分析

关于 Qiagen NV 公司

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Qiagen NV简介



公司代码QGEN

公司名称Qiagen NV

上市日期Sep 01, 1996

CEOBernard (Thierry)

员工数量5765

证券类型Ordinary Share

年结日Sep 01

公司地址Hulsterweg 82

城市VENLO

上市交易所NASDAQ OMX NASDAQ Basic NYSE

国家Netherlands

邮编5912 PL

电话31773556600

网址https://www.qiagen.com/

公司代码QGEN

上市日期Sep 01, 1996

CEOBernard (Thierry)

Qiagen NV公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Roland Sackers

Managing Director, Chief Financial Officer, Member of the Executive Board

383.09K

+143556.00%

Mr. Thierry Bernard

Chief Executive Officer, Managing Director, Member of the Executive Board

312.13K

+134537.00%

Dr. Metin Colpan, Ph.D.

Independent Member of the Supervisory Board

171.79K

-227680.00%

Tallett (Elizabeth E)

Independent Member of the Supervisory Board

47.22K

+4436.00%

Prof. Dr. Ross L. Levine, M.D.

Independent Member of the Supervisory Board

16.27K

+3835.00%

Prof. Dr. Elaine R. Mardis, Ph.D.

Independent Member of the Supervisory Board

3.97K

+3973.00%

Mr. Stephen H. (Steve) Rusckowski

Independent Chairman of the Supervisory Board

24.00

Dr. Toralf Haag, Ph.D.

Independent Member of the Supervisory Board

Dr. Eva Pisa, Ph.D.

Independent Member of the Supervisory Board

Mr. Bert van Meurs

Independent Member of the Supervisory Board

名称

名称/职务

职务

持股

持股变动

Mr. Roland Sackers

Managing Director, Chief Financial Officer, Member of the Executive Board

383.09K

+143556.00%

Mr. Thierry Bernard

Chief Executive Officer, Managing Director, Member of the Executive Board

312.13K

+134537.00%

Dr. Metin Colpan, Ph.D.

Independent Member of the Supervisory Board

171.79K

-227680.00%

Tallett (Elizabeth E)

Independent Member of the Supervisory Board

47.22K

+4436.00%

Prof. Dr. Ross L. Levine, M.D.

Independent Member of the Supervisory Board

16.27K

+3835.00%

Prof. Dr. Elaine R. Mardis, Ph.D.

Independent Member of the Supervisory Board

3.97K

+3973.00%

收入明细

单位: USD更新时间: 1月6日周二

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

业务USD

名称

营收

占比

Consumables and Related Revenues

481.20M

90.35%

Instrumentation

51.38M

9.65%

地区USD

名称

营收

占比

United States

286.67M

53.83%

Europe & Middle East & Africa

172.58M

32.40%

Asia, Pacific & Rest of the World

73.33M

13.77%

业务

地区

业务USD

名称

营收

占比

Consumables and Related Revenues

481.20M

90.35%

Instrumentation

51.38M

9.65%

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

Wellington Management Company, LLP

10.76%

MFS Investment Management

10.56%

The Vanguard Group, Inc.

4.30%

T. Rowe Price International Ltd

3.47%

DWS Investment GmbH

2.13%

其他

68.78%

持股股东

占比

Wellington Management Company, LLP

10.76%

MFS Investment Management

10.56%

The Vanguard Group, Inc.

4.30%

T. Rowe Price International Ltd

3.47%

DWS Investment GmbH

2.13%

其他

68.78%

股东类型

持股股东

占比

Investment Advisor/Hedge Fund

48.66%

Investment Advisor

26.06%

Research Firm

5.08%

Pension Fund

1.63%

Sovereign Wealth Fund

1.60%

Hedge Fund

1.10%

Bank and Trust

1.09%

Individual Investor

0.44%

Insurance Company

0.07%

其他

14.27%

机构持股



更新时间: 1月1日周四

报告期

机构数

持股数

持股占比

持股变动

2025Q4

988

176.43M

85.64%

-25.04M

2025Q3

996

177.81M

82.00%

-32.33M

2025Q2

996

189.55M

87.53%

+6.64M

2025Q1

1017

179.03M

82.67%

+27.58M

2024Q4

1010

129.03M

59.70%

-70.06M

2024Q3

1010

183.22M

84.72%

-23.62M

2024Q2

1002

184.34M

84.75%

+8.40M

2024Q1

988

165.20M

76.61%

-7.18M

2023Q4

993

165.11M

76.72%

-10.52M

2023Q3

987

159.93M

74.32%

-12.21M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Wellington Management Company, LLP

23.33M

10.76%

-2.69M

-10.35%

Sep 30, 2025

MFS Investment Management

22.91M

10.56%

-570.88K

-2.43%

Sep 30, 2025

The Vanguard Group, Inc.

9.33M

4.3%

+169.45K

+1.85%

Sep 30, 2025

T. Rowe Price International Ltd

7.52M

3.47%

+1.59M

+26.73%

Sep 30, 2025

DWS Investment GmbH

4.62M

2.13%

+1.32M

+39.94%

Sep 30, 2025

EARNEST Partners, LLC

4.21M

1.94%

+6.14K

+0.15%

Sep 30, 2025

Amundi Asset Management, SAS

4.15M

1.91%

+170.89K

+4.30%

Sep 30, 2025

Boston Partners

4.02M

1.85%

+594.42K

+17.37%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

3.98M

1.84%

-16.38M

-80.43%

Sep 30, 2025

BofA Global Research (US)

3.61M

1.66%

+2.63M

+269.19%

Oct 21, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

First Trust Nasdaq Lux Digi Health Solutions ETF

4.04%

Global X Genomics & Biotechnology ETF

3.81%

Invesco Biotechnology & Genome ETF

2.54%

VanEck Biotech ETF

1.79%

ROBO Global Healthcare Technology & Innovation ETF

1.51%

Pacer US Large Cap Cash Cows Growth Leaders ETF

1.26%

iShares Health Innovation Active ETF

1.21%

First Trust Health Care Alphadex Fund

0.91%

Franklin Genomic Advancements ETF

0.86%

WisdomTree International Multifactor Fund

0.72%

First Trust Nasdaq Lux Digi Health Solutions ETF

占比4.04%

Global X Genomics & Biotechnology ETF

占比3.81%

Invesco Biotechnology & Genome ETF

占比2.54%

VanEck Biotech ETF

占比1.79%

ROBO Global Healthcare Technology & Innovation ETF

占比1.51%

Pacer US Large Cap Cash Cows Growth Leaders ETF

占比1.26%

iShares Health Innovation Active ETF

占比1.21%

First Trust Health Care Alphadex Fund

占比0.91%

Franklin Genomic Advancements ETF

占比0.86%

WisdomTree International Multifactor Fund

占比0.72%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

May 07, 2025

QGEN.NB Final Cash Dividend of gross USD 0.25 paid on Jul 10, 2025 going ex on Jul 02, 2025

Jul 02, 2025

Jul 10, 2025

Jul 02, 2025

拆合股



公告日期

类型

比率

Jan 17, 2025

Merger

36→35

Jan 17, 2025

Merger

36→35

Jan 17, 2025

Merger

36→35

Jan 17, 2025

Merger

36→35

Jan 18, 2024

Merger

25→24.25

Jan 18, 2024

Merger

25→24.25

公告日期

类型

比率

Jan 17, 2025

Merger

36→35

Jan 17, 2025

Merger

36→35

Jan 17, 2025

Merger

36→35

Jan 17, 2025

Merger

36→35

Jan 18, 2024

Merger

25→24.25

Jan 18, 2024

Merger

25→24.25

Jan 18, 2024

Merger

25→24.25

Jan 18, 2024

Merger

25→24.25

常见问题

Qiagen NV的前五大股东是谁？



Qiagen NV 的前五大股东如下：
Wellington Management Company, LLP持有股份：23.33M，占总股份比例：10.76%。
MFS Investment Management持有股份：22.91M，占总股份比例：10.56%。
The Vanguard Group, Inc.持有股份：9.33M，占总股份比例：4.30%。
T. Rowe Price International Ltd持有股份：7.52M，占总股份比例：3.47%。
DWS Investment GmbH持有股份：4.62M，占总股份比例：2.13%。